These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17409392)

  • 21. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
    Chauhan D; Velankar M; Brahmandam M; Hideshima T; Podar K; Richardson P; Schlossman R; Ghobrial I; Raje N; Munshi N; Anderson KC
    Oncogene; 2007 Apr; 26(16):2374-80. PubMed ID: 17016430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
    Kuroda J; Kimura S; Strasser A; Andreeff M; O'Reilly LA; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Tabe Y; Taniwaki M; Maekawa T
    Cell Death Differ; 2007 Sep; 14(9):1667-77. PubMed ID: 17510658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction.
    Hahm ER; Arlotti JA; Marynowski SW; Singh SV
    Clin Cancer Res; 2008 Feb; 14(4):1248-57. PubMed ID: 18281560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.
    Kline MP; Rajkumar SV; Timm MM; Kimlinger TK; Haug JL; Lust JA; Greipp PR; Kumar S
    Leukemia; 2007 Jul; 21(7):1549-60. PubMed ID: 17460700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression.
    Olberding KE; Wang X; Zhu Y; Pan J; Rai SN; Li C
    Cancer Biol Ther; 2010 Nov; 10(9):918-29. PubMed ID: 20818182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
    Huang S; Sinicrope FA
    Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.
    Qin JZ; Xin H; Sitailo LA; Denning MF; Nickoloff BJ
    Cancer Res; 2006 Oct; 66(19):9636-45. PubMed ID: 17018621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the Bcl-2 family antagonist ABT-737 in collagen-induced arthritis.
    Lawlor KE; Smith SD; van Nieuwenhuijze A; Huang DC; Wicks IP
    J Leukoc Biol; 2011 Oct; 90(4):819-29. PubMed ID: 21719460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
    Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD
    Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells].
    Chen ZJ; Zhang B; Pan SH; Zhao HM; Zhang Y; Feng WH; Li YY; Cao XC
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):891-5. PubMed ID: 22340096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts.
    Ugarenko M; Nudelman A; Rephaeli A; Kimura K; Phillips DR; Cutts SM
    Biochem Pharmacol; 2010 Feb; 79(3):339-49. PubMed ID: 19737541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis.
    Meynet O; Bénéteau M; Jacquin MA; Pradelli LA; Cornille A; Carles M; Ricci JE
    Leukemia; 2012 May; 26(5):1145-7. PubMed ID: 22076465
    [No Abstract]   [Full Text] [Related]  

  • 33. Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death.
    Tajeddine N; Galluzzi L; Kepp O; Hangen E; Morselli E; Senovilla L; Araujo N; Pinna G; Larochette N; Zamzami N; Modjtahedi N; Harel-Bellan A; Kroemer G
    Oncogene; 2008 Jul; 27(30):4221-32. PubMed ID: 18362892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL.
    Ezzoukhry Z; Louandre C; François C; Saidak Z; Godin C; Mazière JC; Galmiche A
    Mol Pharmacol; 2011 Jun; 79(6):997-1004. PubMed ID: 21393385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
    Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL
    Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
    Chen S; Dai Y; Pei XY; Grant S
    Mol Cell Biol; 2009 Dec; 29(23):6149-69. PubMed ID: 19805519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. S1, a novel pan-BH3 mimetic, induces apoptosis in Mcl-1-overexpressing cells through Bak.
    Song T; Chang X; Zhang Z; Liu Y; Shen X
    J Pharmacol Sci; 2012; 119(4):330-40. PubMed ID: 22814102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
    Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y
    Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
    Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S
    Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines.
    Xu H; Krystal GW
    Clin Cancer Res; 2010 Sep; 16(17):4392-400. PubMed ID: 20732961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.